Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Clinical Research Oncology Market Trends GLP-1 Drugs Regulatory Approval Obesity Treatment Obesity Treatments Regulatory Affairs

Bristol Myers Squibb to Build $2.3 Billion Modular Manufacturing Campus in Houston

It anchors BMS’s five-year $40 billion push to expand U.S. drug production.

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

Reuters Says There Were No AstraZeneca‑Bristol Myers Merger Talks

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Baron Capital Reaffirms Long-Term Bullish View on Health Care and Repositions Fund

AstraZeneca in Talks With Bristol Myers on Potential $400 Billion Merger

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

California Supreme Court Rejects 'Duty to Innovate' and Dismisses Negligence Claims Against Gilead

Oral Semaglutide Linked to Fewer Heavy Drinking Days in Small Randomized Trial

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

Wall Street Unanimously Bullish on Teva as Austedo Fuels Turnaround

argenx Posts $1.52 Billion Quarter as VYVGART Readouts Loom

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin